Powered by

-Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP

NORTHVALE, N.J. - Elite Pharmaceuticals, Inc. ('Elite' or the 'Company') (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Phendimetrazine Tartrate Tablets USP, 35 mg.

Based on recent QuintilesIMS Health data from March 2017, the retail sales for this product is approximately

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox